Skip to main content

Table 2 The sFLC concentrations and abnormal ratios of the investigated 186 patients

From: Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience

Variable Baseline After relapse
IgD subtype (n = 13) Non-IgD subtypes (n = 173)a P value IgD subtype (n = 13) Non-IgD subtypes (n = 96) P value
sFLC [mg/L; median (range)]
 κ 12.10 (8.54–186.40) 25.80 (1.49–17,780.00) 0.567 15.60 (8.50–1708.00) 56.00 (7.49–4541.00) 0.655
 λ 129.70 (8.46–4303.00) 28.80 (1.33–17,600.00) 0.151 583.86 (10.51–1092.00) 687.00 (1.33–4000.00) 0.412
κ/λ < 0.01 or > 100 [cases (%)] 4 (30.78) 13 (7.51) 0.021 6 (46.15) 7 (7.29) < 0.001
  1. sFLC serum free light chain, IgD immunoglobulin D
  2. aSerum-free light chains were only available for 173 cases of MM patients at the time of diagnosis